In Promotional Labeling, Size Matters

Law360, New York (February 17, 2012, 1:34 PM ET) -- The U.S. Food and Drug Administration recently published final guidance to clarify the requirements for the use of product names in promotional labeling and advertising for prescription drugs, including biological drug products. This article provides a brief summary of the guidance and its implications.

On Jan. 24, 2012, the U.S. Food and Drug Administration (FDA) posted final guidance entitled Product Name Placement, Size and Prominence in Advertising and Promotional Labeling.

The final guidance, which modifies a draft guidance issued in January 1999, is intended to clarify...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required